-
Publication Venue For
-
The association between coronary graft patency and clinical status in patients with coronary artery disease..
42:1433-1441.
2021
-
Genome-wide analysis identifies novel susceptibility loci for myocardial infarction..
42:919-933.
2021
-
Antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention: balance best with double antithrombotic therapy..
41:4505-4507.
2020
-
Predicting outcome in cardiac arrest: some progress, but more work needed..
41:4518-4520.
2020
-
Managing patients with ST-elevation myocardial infarction and multivessel disease: is the story complete?.
41:4111-4113.
2020
-
Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation..
41:4037-4046.
2020
-
Towards a better standard for defining high bleeding risk patients: can we now translate this into a better practice?.
41:3750-3752.
2020
-
Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS..
41:3533-3545.
2020
-
Intracoronary ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR): a randomized, placebo-controlled, double-blinded trial..
41:3451-3458.
2020
-
Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes..
41:3132-3140.
2020
-
Prevention of cardiovascular disease: time for a course correction..
41:3016-3017.
2020
-
Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis..
41:2248-2258.
2020
-
Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)..
41:2109-2117.
2020
-
Novel approaches to the management of chronic systolic heart failure: future directions and unanswered questions..
41:1764-1774.
2020
-
Call me maybe? The right time and place for BPAs in EHRs..
41:1097-1099.
2020
-
Development of an international standard set of outcome measures for patients with atrial fibrillation: a report of the International Consortium for Health Outcomes Measurement (ICHOM) atrial fibrillation working group..
41:1132-1140.
2020
-
Impact of renin-angiotensin system inhibitors on clinical outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement: an analysis of from the PARTNER 2 trial and registries..
41:943-954.
2020
-
Antithrombotic therapy after acute coronary syndrome and/or percutaneous coronary intervention in atrial fibrillation: finding the sweet spot..
40:3768-3770.
2019
-
Must I keep taking all these medicines? Optimizing diuretics in chronic heart failure..
40:3613-3615.
2019
-
Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial..
40:3345-3352.
2019
-
Continuous anticoagulation with catheter ablation: answers and questions..
40:3022-3025.
2019
-
Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial..
40:2801-2809.
2019
-
Management of cardiogenic shock complicating myocardial infarction: an update 2019..
40:2671-2683.
2019
-
Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk..
40:2632-2653.
2019
-
The optimal antithrombotic regimen to prevent post-CABG adverse events: an ongoing controversy..
40:2441-2443.
2019
-
The continuous heart failure spectrum: moving beyond an ejection fraction classification..
40:2155-2163.
2019
-
Application of net reclassification index to non-nested and point-based risk prediction models: a review..
40:1880-1887.
2019
-
Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials..
40:1492-1500.
2019
-
Reply to letter by Bamford et al. regarding the article: Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial..
40:1568.
2019
-
Atrial fibrillation ablation in practice: assessing CABANA generalizability..
40:1257-1264.
2019
-
Risk stratification for stroke in atrial fibrillation: a critique..
40:1294-1302.
2019
-
Ambulatory heart rate reduction after catheter-based renal denervation in hypertensive patients not receiving anti-hypertensive medications: data from SPYRAL HTN-OFF MED, a randomized, sham-controlled, proof-of-concept trial..
40:743-751.
2019
-
Equalization of four cardiovascular risk algorithms after systematic recalibration: individual-participant meta-analysis of 86 prospective studies..
40:621-631.
2019
-
Fourth universal definition of myocardial infarction (2018)..
40:237-269.
2019
-
Splanchnic nerve block for decompensated chronic heart failure: splanchnic-HF..
39:4255-4256.
2018
-
Modes and timing of death in 66 252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials..
39:3810-3820.
2018
-
Real-world clinical utility and impact on clinical decision-making of coronary computed tomography angiography-derived fractional flow reserve: lessons from the ADVANCE Registry..
39:3701-3711.
2018
-
An update on the journey towards precision medicine in cardiology..
39:3627-3628.
2018
-
The association between blood pressure and long-term outcomes of patients with ischaemic cardiomyopathy with and without surgical revascularization: an analysis of the STICH trial..
39:3464-3471.
2018
-
Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation..
39:2942-2955.
2018
-
Stroke prevention in atrial fibrillation: re-defining 'real-world data' within the broader data universe..
39:2932-2941.
2018
-
Uninterrupted apixaban for atrial fibrillation ablation is a reasonable alternative, but what is the significance of silent cerebral infarctions?.
39:2956-2958.
2018
-
The incidence and prognostic implications of worsening right ventricular function after surgical or transcatheter aortic valve replacement: insights from PARTNER IIA..
39:2659-2667.
2018
-
Japan-United States of America Harmonized Assessment by Randomized Multicentre Study of OrbusNEich's Combo StEnt (Japan-USA HARMONEE) study: primary results of the pivotal registration study of combined endothelial progenitor cell capture and drug-eluting stent in patients with ischaemic coronary disease and non-ST-elevation acute coronary syndrome..
39:2460-2468.
2018
-
Diabetes and long-term outcomes of ischaemic stroke: findings from Get With The Guidelines-Stroke..
39:2376-2386.
2018
-
Autologous CD34+ cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trials..
39:2208-2216.
2018
-
Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document..
39:2192-2207.
2018
-
Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials: An Academic Research Consortium Initiative..
39:1687-1697.
2018
-
Traumatic injury: another unjustified reason to stop oral anticoagulation for atrial fibrillation..
39:1706-1708.
2018
-
Atrial fibrillation ablation alone or atrial fibrillation ablation plus an antiarrhythmic drug?.
39:1438-1441.
2018
-
Cardiomyopathy in Friedreich's Ataxia..
39:631.
2018
-
A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score..
39:477-485.
2018
-
Improving outcomes after catheter ablation of atrial fibrillation: better patient selection, better procedure, or both?.
39:450-452.
2018
-
Oral anticoagulation: a step toward solving the puzzle of dementia related to atrial fibrillation?.
39:461-463.
2018
-
Clopidogrel reloading for patients with acute myocardial infarction already on clopidogrel therapy..
39:193-200.
2018
-
Relationship between microvascular obstruction and adverse events following primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an individual patient data pooled analysis from seven randomized trials..
38:3502-3510.
2017
-
Staging classification of aortic stenosis based on the extent of cardiac damage..
38:3351-3358.
2017
-
Blood pressure and in-hospital outcomes in patients presenting with ischaemic stroke..
38:2827-2835.
2017
-
Global position paper on cardiovascular regenerative medicine..
38:2532-2546.
2017
-
Interruption of non-vitamin K antagonist anticoagulants in patients undergoing planned invasive procedures: how long is long enough?.
38:2440-2443.
2017
-
Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF)..
38:2364-2373.
2017
-
Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary..
38:2137-2149.
2017
-
Moving beyond regression techniques in cardiovascular risk prediction: applying machine learning to address analytic challenges..
38:1805-1814.
2017
-
Succinate dehydrogenase gene mutation with cardiac paraganglioma: multimodality imaging and pathological correlation..
38:1853-1854.
2017
-
HIV infection, ACS, PCI and high platelet reactivity: ingredients for a perfect thrombotic storm..
38:1687-1689.
2017
-
Infarct size, left ventricular function, and prognosis in women compared to men after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: results from an individual patient-level pooled analysis of 10 randomized trials..
38:1656-1663.
2017
-
Left atrial appendage occlusion: rationale, evidence, devices, and patient selection..
38:869-876.
2017
-
Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial..
38:804-810.
2017
-
Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial..
38:648-660.
2017
-
A review of sex-specific benefits and risks of antithrombotic therapy in acute coronary syndrome..
38:165-171.
2017
-
A view from the side-line..
37:3488-3489.
2016
-
Genetic cardiovascular risk prediction: are we already there?.
37:3279-3281.
2016
-
Risk stratification in non-ST elevation acute coronary syndromes: searching for the right formula..
37:3111-3113.
2016
-
The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial..
37:2869-2878.
2016
-
Aortic valve surgery and survival in patients with moderate or severe aortic stenosis and left ventricular dysfunction..
37:2276-2286.
2016
-
Outcomes of transfemoral transcatheter aortic valve implantation at hospitals with and without on-site cardiac surgery department: insights from the prospective German aortic valve replacement quality assurance registry (AQUA) in 17 919 patients..
37:2240-2248.
2016
-
Finerenone in heart failure: walking a fine line..
37:2115-2117.
2016
-
Left atrial appendage to great cardiac vein fistula complicating watchman left atrial appendage closure..
37:1602.
2016
-
The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation..
37:1582-1590.
2016
-
Genetic variants and disease: correlate or cause?.
37:1476-1478.
2016
-
Assessing generalizability of trial results in general practice..
37:1154-1157.
2016
-
Deciding about prolonged ticagrelor therapy in coronary clot formers: an ongoing dilemma..
37:1143-1144.
2016
-
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1.
2016
-
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2.
2016
-
Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome..
37:412-422.
2016
-
CardioPulse: Platelet inhibitors and their differences..
37:323-326.
2016
-
Lessons learned and a look to the future: the Chronic Ischemic Heart Disease (CICD) Pilot Registry..
37:161-163.
2016
-
Nox4 NADPH oxidase: emerging from the veil of darkness..
36:3457-3459.
2015
-
Clinical outcomes of fractional flow reserve by computed tomographic angiography-guided diagnostic strategies vs. usual care in patients with suspected coronary artery disease: the prospective longitudinal trial of FFR(CT): outcome and resource impacts study..
36:3359-3367.
2015
-
Atrial fibrillation in heart failure: what should we do?.
36:3250-3257.
2015
-
Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial..
36:3268-3275.
2015
-
The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation.
36:3258-3264.
2015
-
The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation..
36:3258-3264.
2015
-
Management and outcomes in patients with moderate or severe functional mitral regurgitation and severe left ventricular dysfunction..
36:2733-2741.
2015
-
Augmenting outcomes in patients with advanced heart failure..
36:2276-2278.
2015
-
Reversal of right-ventricular dysfunction in pulmonary arterial hypertension following sildenafil therapy..
36:2018.
2015
-
Cardiovascular precision medicine: hope or hype?.
36:1842-1843.
2015
-
Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 1: clinical trial design principles: A consensus document from the mitral valve academic research consortium..
36:1851-1877.
2015
-
Effect of genetic variations on ticagrelor plasma levels and clinical outcomes..
36:1901-1912.
2015
-
Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention..
36:1762-1771.
2015
-
Current worldwide nuclear cardiology practices and radiation exposure: results from the 65 country IAEA Nuclear Cardiology Protocols Cross-Sectional Study (INCAPS)..
36:1689-1696.
2015
-
The detection and treatment of subclinical atrial fibrillation: evaluating the IMPACT of a comprehensive strategy based on remote arrhythmia monitoring..
36:1640-1642.
2015
-
Should patients on vitamin K antagonists be treated differently?.
36:1431-1433.
2015
-
Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial..
36:1264-1272.
2015
-
Management of cardiogenic shock..
36:1223-1230.
2015
-
The end of an electrocardiographic dogma: a prominent R wave in V1 is caused by a lateral not posterior myocardial infarction-new evidence based on contrast-enhanced cardiac magnetic resonance-electrocardiogram correlations..
36:959-964.
2015
-
Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated mutation carriers..
36:847-855.
2015
-
Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program..
36:669-675.
2015
-
Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension..
36:566-575.
2015
-
LCZ696: too good to be true?.
36:410-412.
2015
-
Paravalvular regurgitation after transcatheter aortic valve replacement with the Edwards sapien valve in the PARTNER trial: characterizing patients and impact on outcomes..
36:449-456.
2015
-
The association between biventricular pacing and cardiac resynchronization therapy-defibrillator efficacy when compared with implantable cardioverter defibrillator on outcomes and reverse remodelling..
36:440-448.
2015
-
Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial..
36:385-92a.
2015
-
Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial..
36:288-296.
2015
-
Paradoxical embolism in Ebstein's anomaly..
36:315.
2015
-
Predictors of blood pressure response in the SYMPLICITY HTN-3 trial..
36:219-227.
2015
-
Chest pain in patients with heart failure: why history may matter..
35:3408-3409.
2014
-
Atrial fibrillation, valvular heart disease, and use of target-specific oral anticoagulants for stroke prevention..
35:3323-3325.
2014
-
Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial..
35:3377-3385.
2014
-
Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry..
35:2864-2872.
2014
-
Ameliorating reperfusion injury in STEMI: dead or alive?.
35:2504-2506.
2014
-
Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial..
35:2516-2523.
2014
-
Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial..
35:2524-2529.
2014
-
An unusual cause of dyspnoea in a young man..
35:1855.
2014
-
Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial..
35:1864-1872.
2014
-
Is there a period of liability with initiation of warfarin in patients with atrial fibrillation?.
35:1834-1835.
2014
-
Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial..
35:1873-1880.
2014
-
Diagnosis of pheochromocytoma on physical examination..
35:1705.
2014
-
Statistical considerations in economic evaluations: a guide for cardiologists..
35:1652-1656.
2014
-
Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis..
35:1559-1567.
2014
-
The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial..
35:1541-1550.
2014
-
The organization, function, and outcomes of ST-elevation myocardial infarction networks worldwide: current state, unmet needs and future directions..
35:1526-1532.
2014
-
Early management of atrial fibrillation to prevent cardiovascular complications..
35:1448-1456.
2014
-
Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial..
35:1041-1050.
2014
-
The enigmatic search for optimal DAPT duration..
35:951-954.
2014
-
Large simple trials: really, it can't be that simple!.
35:549-551.
2014
-
Large streamlined trials in cardiovascular disease..
35:544-548.
2014
-
The appropriate and justified use of medical radiation in cardiovascular imaging: a position document of the ESC Associations of Cardiovascular Imaging, Percutaneous Cardiovascular Interventions and Electrophysiology..
35:665-672.
2014
-
Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis..
35:455-469.
2014
-
Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial..
35:224-232.
2014
-
Association between myocardial substrate, implantable cardioverter defibrillator shocks and mortality in MADIT-CRT..
35:106-115.
2014
-
Clinical course of atrial fibrillation in older adults: the importance of cardiovascular events beyond stroke..
35:250-256.
2014
-
Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF..
35:242-249.
2014
-
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial..
35:233-241.
2014
-
Natriuretic peptide-guided heart failure management..
35:16-24.
2014
-
Learning from regional heterogeneity in outcomes of patients with acute myocardial infarction..
34:3171-3172.
2013
-
Physical activity in patients with stable coronary heart disease: an international perspective..
34:3286-3293.
2013
-
Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial..
34:3117-3127.
2013
-
Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF..
34:3128-3136.
2013
-
A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial..
34:2481-2489.
2013
-
Association between resting heart rate, chronotropic index, and long-term outcomes in patients with heart failure receiving β-blocker therapy: data from the HF-ACTION trial..
34:2271-2280.
2013
-
Atrial fibrillation: a spectrum of risk with a uniform treatment effect of novel anticoagulants?.
34:2429-2431.
2013
-
Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial..
34:2464-2471.
2013
-
Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial..
34:1723-1731.
2013
-
New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis..
34:1670-1680.
2013
-
Biomarkers in atrial fibrillation: a clinical review..
34:1475-1480.
2013
-
Phosphate: a novel cardiovascular risk factor..
34:1099-1101.
2013
-
Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis..
34:1204-1214.
2013
-
Evaluation of early percutaneous coronary intervention vs. standard therapy after fibrinolysis for ST-segment elevation myocardial infarction: contribution of weighting the composite endpoint..
34:903-908.
2013
-
Implementation of standardized assessment and reporting of myocardial infarction in contemporary randomized controlled trials: a systematic review..
34:894-902d.
2013
-
Spousal depression, anxiety, and suicide after myocardial infarction..
34:649-656.
2013
-
How country-specific should a country-specific cost-effectiveness analysis be?.
34:166-167.
2013
-
Influence of baseline left ventricular function on the clinical outcome of surgical ventricular reconstruction in patients with ischaemic cardiomyopathy..
34:39-47.
2013
-
Mechanical dyssynchrony evaluated by tissue Doppler cross-correlation analysis is associated with long-term survival in patients after cardiac resynchronization therapy..
34:48-56.
2013
-
Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial..
33:2821-2830.
2012
-
Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice..
33:2782-2795.
2012
-
Clinical update: Remaining challenges and opportunities for improvement in percutaneous transradial coronary procedures..
33:2521-2526.
2012
-
Road mapping ATLAS ACS 2: are we there yet?.
33:2510-2512.
2012
-
Third universal definition of myocardial infarction..
33:2551-2567.
2012
-
Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document..
33:2403-2418.
2012
-
Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study..
33:2151-2162.
2012
-
The association of in-hospital major bleeding with short-, intermediate-, and long-term mortality among older patients with non-ST-segment elevation myocardial infarction..
33:2044-2053.
2012
-
Discriminating clinical features of heart failure with preserved vs. reduced ejection fraction in the community..
33:1734-1741.
2012
-
The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis..
33:1750-1757.
2012
-
Putting risk prediction in atrial fibrillation into perspective..
33:1431-1433.
2012
-
Adjustment of the GRACE score by growth differentiation factor 15 enables a more accurate appreciation of risk in non-ST-elevation acute coronary syndrome..
33:1095-1104.
2012
-
Toward a therapeutic window for antiplatelet therapy in the elderly..
33:1187-1189.
2012
-
Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial..
32:2933-2944.
2011
-
Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes..
32:2945-2953.
2011
-
ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)..
32:2999-3054.
2011
-
Long-term prognosis associated with J-point elevation in a large middle-aged biracial cohort: the ARIC study..
32:3098-3106.
2011
-
Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial..
32:2781-2789.
2011
-
Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy..
32:2412-2419.
2011
-
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment..
32:2387-2394.
2011
-
RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome..
32:2541-2554.
2011
-
Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology..
32:1854-1864.
2011
-
Who should have a routine early invasive approach after fibrinolytic therapy?.
32:1961-1963.
2011
-
Clinical evaluation of cardiovascular devices: principles, problems, and proposals for European regulatory reform. Report of a policy conference of the European Society of Cardiology..
32:1673-1686.
2011
-
Response to preventive cardiac resynchronization therapy in patients with ischaemic and nonischaemic cardiomyopathy in MADIT-CRT..
32:1622-1630.
2011
-
The future of clinical trials in secondary prevention after acute coronary syndromes..
32:1583-1589.
2011
-
Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study..
32:1519-1534.
2011
-
Additional impact of morning haemostatic risk factors and morning blood pressure surge on stroke risk in older Japanese hypertensive patients..
32:574-580.
2011
-
Fractal analysis of retinal microvasculature and coronary heart disease mortality..
32:422-429.
2011
-
Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium..
32:205-217.
2011
-
Early routine percutaneous coronary intervention after fibrinolysis vs. standard therapy in ST-segment elevation myocardial infarction: a meta-analysis..
31:2156-2169.
2010
-
Non-culprit coronary artery percutaneous coronary intervention during acute ST-segment elevation myocardial infarction: insights from the APEX-AMI trial..
31:1701-1707.
2010
-
Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial..
31:1708-1716.
2010
-
Delay to reperfusion in patients with acute myocardial infarction presenting to acute care hospitals: an international perspective..
31:1328-1336.
2010
-
Factors related to heart rupture in acute coronary syndromes in the Global Registry of Acute Coronary Events..
31:1449-1456.
2010
-
Influence of functional deficiency of complement mannose-binding lectin on outcome of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention..
31:1181-1187.
2010
-
Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis..
31:1257-1265.
2010
-
The gene expression profile of patients with new-onset heart failure reveals important gender-specific differences..
31:1188-1196.
2010
-
Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria..
31:806-814.
2010
-
Towards a new order in cardiovascular medicine: re-engineering through global collaboration..
31:911-917.
2010
-
Clinical trials and registries in cardiovascular disease: competitive or complementary?.
31:520-521.
2010
-
Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The global registry of acute coronary events..
31:667-675.
2010
-
Resolution of ST-segment depression: A new prognostic marker in ST-segment elevation myocardial infarction..
31:573-581.
2010
-
The association of admission heart rate and in-hospital cardiovascular events in patients with non-ST-segment elevation acute coronary syndromes: results from 135 164 patients in the CRUSADE quality improvement initiative..
31:552-560.
2010
-
Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications..
31:227-235.
2010
-
Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial..
31:211-221.
2010
-
Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes..
31:50-58.
2010
-
Transfusion and mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention..
30:2575-2583.
2009
-
Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry..
30:2318-2326.
2009
-
Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial..
30:2226-2232.
2009
-
Reperfusion before percutaneous coronary intervention in ST-elevation myocardial infarction patients is associated with lower N-terminal pro-brain natriuretic peptide levels during follow-up, irrespective of pre-treatment with full-dose fibrinolysis..
30:2213-2219.
2009
-
Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial..
30:2019-2028.
2009
-
Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial..
30:1457-1466.
2009
-
Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT)..
30:1450-1456.
2009
-
Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials..
30:1245-1253.
2009
-
Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes..
30:1195-1202.
2009
-
Pre-operative homocysteine levels and morbidity and mortality following cardiac surgery..
30:995-1004.
2009
-
Reperfusion ventricular arrhythmia 'bursts' predict larger infarct size despite TIMI 3 flow restoration with primary angioplasty for anterior ST-elevation myocardial infarction..
30:757-764.
2009
-
Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes..
30:655-661.
2009
-
Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure..
30:338-345.
2009
-
ESC Forum on Drug Eluting Stents European Heart House, Nice, 27-28 September 2007..
30:152-161.
2009
-
Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme..
29:3022-3028.
2008
-
Is thrombogenesis related to residual platelet function in ischaemic heart disease?.
29:3065.
2008
-
Modifiable risk factors control and its relationship with 1 year outcomes after coronary artery bypass surgery: insights from the REACH registry..
29:3052-3060.
2008
-
Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme..
29:2641-2650.
2008
-
Patterns and prognostic implications of low high-density lipoprotein levels in patients with non-ST-segment elevation acute coronary syndromes..
29:2480-2488.
2008
-
A smoker's paradox in patients hospitalized for heart failure: findings from OPTIMIZE-HF..
29:1983-1991.
2008
-
Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial..
29:1827-1833.
2008
-
Determinants of thrombin generation, fibrinolytic activity, and endothelial dysfunction in patients on dual antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow's triad..
29:1729-1738.
2008
-
Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme..
29:1377-1385.
2008
-
Is female gender an independent risk factor for early mortality in coronary artery bypass surgery? (Abstract).
19 (Suppl):413-413.
1998
-
Risk stratification in coronary surgery.
19 (Suppl):413-413.
1998
-
The association between vegetation size and surgical treatment on 6-month mortality in left-sided infective endocarditis.
2019
-
Diuretic response in acute heart failure: clinical characteristics and prognostic significance.
2014